Aim of the EU project FORGETDIABETES (supported by H2020-FETPROACT, n.951933) is to develop a fully implantable AID system. To assess and address attitudes and barriers to implantable AID solutions, a new assessment tool was developed. Associations of attitudes and barriers with the readiness to use an implantable AID solution were analyzed. The newly developed questionnaire consists of four subscales assessing “glycemic benefits” (e.g. protection from complications), “mental benefits” (e.g. less thinking about diabetes), “technical barriers” (e.g. side effects), and “emotional barriers” (e.g. loss of control). A total of 366 people with type 1 diabetes (45.9% insulin pump, 27.0% AID) completed the questionnaire and indicated whether they would use an implantable AID system. Associations of the four subscales with the decision to use an implantable AID were analyzed via a logistic regression. A one-point increase in emotional and technical barriers reduced the readiness to use an implantable AID by 49% and 60%, respectively. A one-point increase in mental and glycemic benefits increased the readiness by 30 and 100%, respectively (Figure 1). Human factors assessed via the newly developed assessment tool have an impact on the readiness to use an implantable AID system. These human factors can be systematically assessed via the assessment tool and should be addressed when implantable AID are available.

Disclosure

D. Ehrmann: Advisory Panel; Dexcom, Inc. Speaker's Bureau; Dexcom, Inc., Sanofi-Aventis Deutschland GmbH. Advisory Panel; Roche Diabetes Care. Speaker's Bureau; Roche Diabetes Care, Berlin-Chemie AG. K. Finke-Groene: None. B. Kulzer: Advisory Panel; Abbott Diagnostics, Berlin-Chemie AG, Dexcom, Inc., Sanofi, embecta, Novo Nordisk, Roche Diabetes Care. Speaker's Bureau; Bayer Inc., Insulet Corporation, Lilly Diabetes. N. Hermanns: Speaker's Bureau; Berlin-Chemie AG, Sanofi-Aventis Deutschland GmbH. Research Support; Sanofi-Aventis Deutschland GmbH. Speaker's Bureau; Roche Diabetes Care. Research Support; Roche Diabetes Care. Speaker's Bureau; Dexcom, Inc. Advisory Panel; Abbott Diagnostics, Ypsomed AG.

Funding

This project has received funding from the European Union’s Horizon 2020 research and innovation programme (No 951933)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.